Welcome to ourAnnual Report 2019

Pioneering for patients

Discover more about our historic year

Letter from the management

We are very proud of the deal with our collaboration partner Gilead announced in the summer, and we’re convinced that it offers us the opportunity to maximize our potential, to the benefit of patients, society and shareholders. Onno van de Stolpe, CEO
Letter from the management

Financial highlights

Group revenues

895.9 million

At a glance

Cash position

5780.8 million

At a glance

Deferred income

3000.6 million

At a glance

R&D expenditure

427.3 million

At a glance

Meet our executive committee

Corporate social responsibility

We believe we have a responsibility to ensure our actions not only benefit our main stakeholders, but also society as a whole. At Galapagos, being socially responsible is already a consideration in everything we do.

Our commitment